[
  {
    "ts": "2025-05-19T12:00:00+00:00",
    "headline": "Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing",
    "summary": "WALTHAM, Mass., May 19, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.",
    "url": "https://finance.yahoo.com/news/revvity-euroimmun-unveils-fully-automated-120000331.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "11c8abb8-e238-3494-b3ae-80257df36784",
      "content": {
        "id": "11c8abb8-e238-3494-b3ae-80257df36784",
        "contentType": "STORY",
        "title": "Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing",
        "description": "",
        "summary": "WALTHAM, Mass., May 19, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.",
        "pubDate": "2025-05-19T12:00:00Z",
        "displayTime": "2025-05-19T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/99a5069d26f1472e875a78077abe4cf8",
          "originalWidth": 784,
          "originalHeight": 320,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XXTtklcNwLONIZvD.BzXWQ--~B/aD0zMjA7dz03ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/99a5069d26f1472e875a78077abe4cf8.cf.webp",
              "width": 784,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yudTL9LRBA5A9OhqOibobw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/99a5069d26f1472e875a78077abe4cf8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revvity-euroimmun-unveils-fully-automated-120000331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revvity-euroimmun-unveils-fully-automated-120000331.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]